Multivirus-specific T cells - ViraCyte

Drug Profile

Multivirus-specific T cells - ViraCyte

Alternative Names: Multivirus-specific T cell therapy; Viralym-M

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Baylor College of Medicine
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Herpesvirus infections; Polyomavirus infections

Most Recent Events

  • 18 Jul 2017 Efficacy data from a phase II trial in Adenovirus infection, BK virus, Cytomegalovirus, Epstein-barr virus and Human herpesvirus released by Viracyte
  • 05 Jul 2017 ViraCyte receives SBIR grant from National Heart, Lung and Blood Institute for T cell immunotherapy development in Polyomavirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top